BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
10.39
+1.35 (14.93%)
Aug 3, 2026, 1:30 PM EDT - Market open
BioAge Labs Employees
As of December 31, 2025, BioAge Labs had 62 total employees, including 60 full-time and 2 part-time employees. The number of employees decreased by 2 or -3.13% compared to the previous year.
Employees
62
Change (1Y)
-2
Growth (1Y)
-3.13%
Revenue / Employee
$166,387
Profits / Employee
-$1,450,484
Market Cap
461.86M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 62 | -2 | -3.13% | 60 | 2 |
| Dec 31, 2024 | 64 | 8 | 14.29% | 62 | 2 |
| Jun 30, 2024 | 60 | - | - | 58 | 2 |
| Mar 31, 2024 | 56 | - | - | 54 | 2 |
| Dec 31, 2023 | 56 | - | - | 54 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Canopy Growth | 1,128 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Evolus | 350 |
| Anika Therapeutics | 235 |
| Akebia Therapeutics | 194 |
BIOA News
- 2 days ago - BioAge Labs price target lowered to $25 from $36 at Roth Capital - TheFly
- 2 days ago - BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi - TheFly
- 3 days ago - BioAge Labs price target lowered at Jefferies after Novo trial miss - TheFly
- 3 days ago - BioAge Labs price target lowered to $50 from $60 at Oppenheimer - TheFly
- 6 weeks ago - BioAge Labs doses first participant in QUELL-CV trial of BGE-102 - TheFly
- 6 weeks ago - BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk - GlobeNewsWire
- 7 weeks ago - BioAge Labs Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - BioAge Labs Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts